FT-4202, a selective pyruvate kinase R activator for sickle cell disease
Experimental Hematology · 2025
DOI: 10.1016/j.exphem.2024.104673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Hematology, 2025. Verfasst von Anna Ericsson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Forma Therapeutics, Inc., Watertown, MA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Pyruvate Kinase, Enzyme Activators. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anemia in patients with sickle cell disease (SCD) increases 2,3-diphosphoglycerate (2,3-DPG), decreasing hemoglobin-oxygen (HbO2) affinity to improve oxygen offloading and promote hemoglobin polymerization (sickling) of red blood cells (RBCs). We report the discovery of FT-4202, an investigational, selective pyruvate kinase type-R (PKR) activator with a multimodal mechanism of action and potential to increase ATP and decrease 2,3-DPG, resulting in increased HbO2 affinity, decreased Hb polymerization, and improved RBC health. FT-4202 was identified via structure-enabled lead optimization medicinal chemistry using X-ray crystallography, molecular modeling, and thermal shift assays. FT-4202, an allosteric PKR activator, stabilizes the tetrameric enzyme and increases PKR activity in human and mouse RBCs in vitro. Seven-day oral administration of FT-4202 in Berkeley SCD mice reduced 2,3-DPG, increased HbO2 affinity, and reduced RBC sickling versus control. There were no adverse in vitro safety findings. FT-4202 offers a therapeutic opportunity to modify the course of SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Forma Therapeutics, Inc., Watertown, MA.
- University of California San Francisco, Oakland, CA.
- Novo Nordisk, Watertown, MA. Electronic address: sygx@novonordisk.com.
Zitieren
APA
Ericsson, A., Richard, D. J., Wilker, E., Lancia, D. R., Fessler, S., Troccolo, P., Zheng, X., Toms, A., Dinsmore, C., Yao, L., Kuypers, F. A., Larkin, S., Marcotte, D., Fulzele, K., Ribadeneira, M., Guichard, S. M., & Marshall, G. (2025). FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. https://doi.org/10.1016/j.exphem.2024.104673
Vancouver
Ericsson A, Richard DJ, Wilker E, Lancia DR, Fessler S, Troccolo P, et al. FT-4202, a selective pyruvate kinase R activator for sickle cell disease. Experimental Hematology. 2025. doi:10.1016/j.exphem.2024.104673
BibTeX
@article{Ericsson2025,
author = {Ericsson, Anna and Richard, David J and Wilker, Erik and Lancia, David R and Fessler, Shawn and Troccolo, Paul and Zheng, Xiaozhang and Toms, Angela and Dinsmore, Christopher and Yao, Lili and Kuypers, Frans A and Larkin, Sandra and Marcotte, Douglas and Fulzele, Keertik and Ribadeneira, Maria and Guichard, Sylvie M and Marshall, Gary},
title = {FT-4202, a selective pyruvate kinase R activator for sickle cell disease},
journal = {Experimental Hematology},
year = {2025},
doi = {10.1016/j.exphem.2024.104673}
}
EUVIMED